After 12 months of ARV treatment, 66 patients were followed up HBV DNA, the median HBV DNA decreased significantly and 47% had HBV DNA seroconversion from negative to positive, with 2 patients had HBV DNA increased from baseline; and 32.1% of patients had HBeAg seroconversion; the rate of HBsAg loss was 10.3%.